UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the Centers for ...

Discover a study on SIP-BMG for bladder neck stenosis, revealing over 90% success and lasting improvements in urinary ...

The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...

Background: This study explores the risk factors for ureteral stricture and tumor recurrence after transurethral resection of bladder tumor (TURBT) in patients with paraureteral bladder cancer, aiming ...

Urothelial carcinoma is the most common bladder cancer, with stage 1 indicating early-stage disease confined to the bladder lining. Diagnosis involves urinalysis, cystoscopy, TURBT, and imaging to ...

Introduction Muscle-invasive bladder cancer (MIBC) is an aggressive type of cancer. About 50% of patients will die from the disease within 5 years despite radical treatment. This implies that in many ...

Panelists discuss how patients with recurrent low-grade bladder cancer, particularly women who may face additional anatomical challenges during transurethral resection of bladder tumor (TURBT) ...

24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE ...

Introduction: The aim of the present prospective-randomized study was to compare perioperative outcomes and complications of bipolar and monopolar TURBT for lateral wall-located non-muscle invasive ...